0.38 USD
▲+0.03+37.17%
盘后 0.57 +103.18%
2026-08-03
市值
$5.65M
市盈率
—
EPS
-3.01
股息率
—
52 周区间
0.23 – 2.75
成交量
182.04M
Beta
0.90
目标价
—
52W 低 0.2352W 高 2.75
价格走势
公司简介
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company’s lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the...